Jazz Pharma to Gain Access to Epidiolex in $7.2B Acquisition of GW Pharma

Jazz Pharma to Gain Access to Epidiolex in $7.2B Acquisition of GW Pharma

288456

Jazz Pharma to Gain Access to Epidiolex in $7.2B Acquisition of GW Pharma

Jazz Pharmaceuticals is set to acquire GW Pharmaceuticals and gain access to a diversified pipeline of cannabis-based medications, including Epidiolex (cannabidiol), which is approved to treat seizures in patients with therapy-resistant forms of epilepsy, such as Dravet syndrome. The transaction, which involves a cash-and-stock deal totaling about $7.2 billion, was unanimously approved by the boards of directors of both companies and is expected to be completed in the second quarter of the year. Once the…

You must be logged in to read/download the full post.